Panacea Biotec valuation

Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
Price multiples — at each FY-end close
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
2.42×————
3.00×————
Enterprise multiples
2.92×————
898.37×————
−64.76×————
Yield
−0.4%————
−1.9%————
Reference — adjusted share basis
₹329.05————
−₹1.16−₹0.88−₹1.37−₹0.19−₹5.51
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

PANACEABIO₹329.05

Panacea Biotec Limited

· Pharma & Health
₹ CrorePeersSAIPARENTHIKALINDOCODCALWINDLASHESTERBIOSOLARASYNCOMFMcap ₹2,017 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
Multiples — ₹ Crore base
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Price Multiples — at each FY-end close
P/B————2.42
P/Sales————3.00
Enterprise Multiples
EV/Sales————2.92
EV/EBITDA————898.37
EV/EBIT————-64.76
Yield
Earnings Yield %————-0.35
FCF Yield %————-1.85
Reference — adjusted share basis
Price (FY-end close, adj.)————329.05
EPS (adj.)-5.51-0.19-1.37-0.88-1.16
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.